Item 1.02. Termination of a Material Definitive Agreement.

Oragenics, Inc. (the "Company" or "we") has a commitment to the continued research and development of lantibiotics for the treatment of infectious diseases. In an effort to strengthen and streamline that commitment, on September 22, 2021, the Company and Eleszto Genetika, Inc. mutually terminated the amended and restated worldwide exclusive channel collaboration agreement dated March 1, 2021 (the "Lantibiotic ECC") pursuant to which the Company was pursuing the development of OG716 as a lead product candidate for the treatment of C. diff.

As a result of the mutual termination of the Lantibiotic ECC, the Company will cease pre-clinical development of its product candidate OG716 and other compounds covered by the Lantibiotic ECC, all licenses provided pursuant to the Lantibiotic ECC between the parties were terminated and there are no continuing obligations between the parties, except as to confidentiality. The Company made no payments to EGI in connection with the mutual termination. Each party retained all right and title to their own respective intellectual property.

The Company will focus on its continuing independent research and development efforts relative to lantibiotics in order to identify new compounds to pursue.

© Edgar Online, source Glimpses